thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
=== Allergy === An allergic reaction, formally known as type 1 hypersensitivity, is the result of an inappropriate immune response triggering inflammation, vasodilation, and nerve irritation. A common example is hay fever, which is caused by a hypersensitive response by mast cells to allergens. Pre-sensitised mast cells respond by degranulating, releasing vasoactive chemicals such as histamine. These chemicals propagate an excessive inflammatory response characterised by blood vessel dilation, production of pro-inflammatory molecules, cytokine release, and recruitment of leukocytes. Severe inflammatory response may mature into a systemic response known as anaphylaxis.
== Research contributions == Brenner has made multiple contributions to molecular biology and biochemistry, beginning with purification and characterization of the Kex2 proprotein convertase at Stanford. Significant research projects include the role of Ap3A binding in the function of the FHIT tumor suppressor gene, characterization and inhibition of DNA methylation, and discovery of new steps in nicotinamide adenine dinucleotide (NAD) metabolism. Notably, the Brenner laboratory discovered that eukaryotes use nicotinamide riboside (NR) to make NAD+. Bieganowski and Brenner (2004) found that NR is converted to NAD+ through the action of nicotinamide ribose kinases including Nrk1 (yeast and human) and Nrk2 (human). Belenky et al. (Cell, 2007) reported another pathway which turns NR into NAM through the action of nucleosidases Urh1/Pnp1/Meu1 and is Nrk1 independent.
Diagnosis is made with reasonable certainty based on history and clinical examination. X-rays may confirm the diagnosis. The typical changes seen on X-ray include: joint space narrowing, subchondral sclerosis (increased bone formation around the joint), subchondral cyst formation, and osteophytes. The combination of knee pain and osteophytes on x-ray or hip pain and osteophytes on x-ray, has good sensitivity and specificity for the diagnosis of osteoarthritis of those joints. X-rays may not correlate with the findings on physical examination or with the degree of pain, especially in the early course of osteoarthritis, where imaging findings may be relatively normal. In 1990, the American College of Rheumatology, using data from a multi-center study, developed a set of criteria for the diagnosis of hand osteoarthritis based on hard tissue enlargement and swelling of certain joints. These criteria were found to be 92% sensitive and 98% specific for hand osteoarthritis versus other entities such as rheumatoid arthritis and spondyloarthropathies.
==== 2020s ==== On October 28, 2020, Panera announced they would add pizza to their menu to increase dinner options for customers. Panera announced on August 25, 2021, that it had merged with Caribou Coffee and Einstein Bros. Bagels to form Panera Brands. In August 2022, the company announced that it was testing the use of artificial intelligence in its drive-thru lanes via two locations in upstate New York. It used OpenCity's voice ordering technology, Tori. At the time of the announcement, roughly 45% of the chain's locations had drive-thru lanes. In making this move, the firm was joining other firms in the restaurant industry, like McDonald's, Burger King, and Taco Bell, and it came on top of other uses of artificial intelligence at the chain. In September 2022, Panera announced that legacy St. Louis Bread Co. locations outside St. Louis City and St. Louis County would be rebranded as Panera when remodeled, with locations in the inner core of the metro retaining the Bread Co. name. One location in St. Louis County is named Panera as it is a prototype of the "Next Gen" restaurant design. In mid-2023, Panera moved its headquarters from Sunset Hills to Fenton, Missouri, downsizing the square footage by more than half. The move preceded two rounds of corporate layoffs in late 2023 and 2024. In December 2023, it was learned that Panera Bread confidentially filed to go public again. The company was last publicly traded in 2017 before being acquired by JAB Holding for $7.5 billion.
== Origin == The first symptoms of apitoxin (bee venom), that are now thought to be caused by apamin, were described back in 1936 by Hahn and Leditschke. Apamin was first isolated by Habermann in 1965 from Apis mellifera, the Western honey bee. Apamin was named after this bee. Bee venom contains many other compounds, like histamine, phospholipase A2, hyaluronidase, MCD peptide, and the main active component melittin. Apamin was separated from the other compounds by gel filtration and ion exchange chromatography.
Sources: en.wikipedia.org
Aryl nitriles can be synthesized via the Sandmeyer reaction of diazonium salts with copper(I) cyanide or by the Rosenmund-von Braun reaction (direct reaction of an aryl bromide with copper(I) cyanide). Conversion of thiocyanate with aromatic carboxylic acids, known as Letts nitrile synthesis, can be carried out using potassium thiocyanate; lead thiocyanate generally provides higher yields. Aryl iodides can be converted into aromatic nitriles under palladium catalysis with trimethylsilyl cyanide. For example, iodobenzene reacts with trimethylsilyl cyanide in the presence of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) to form benzonitrile. Another palladium-catalyzed route (also employing Pd(PPh3)4) is the decarbonylation of aromatic acyl cyanides. Palladium-catalyzed cyanation of aryl chlorides with potassium cyanide or potassium hexacyanidoferrate(II) has likewise been reported. Quinones can react with trimethylsilyl cyanide to give silylated cyanohydrins, which are subsequently aromatized using phosphorus tribromide. A further approach involves reaction of aryl Grignard or aryllithium reagents with dimethylmalonitrile. Aromatic nitriles are often prepared in the laboratory from the aniline via diazonium compounds. This is the Sandmeyer reaction. It requires transition metal cyanides.
== Justification == Topical drug delivery is a route of administering drugs via the skin with the intent to provide therapeutic effects. This system usually provides a local effect on certain organs. In ancient times, people used herbs on wounds for relieving the inflammatory effect or as pain relievers. There are numerous dosage forms that can be used topically, including cream, ointment, lotion, patches, and other forms. The topical use has many advantages: avoiding first pass metabolism which can increase its bioavailability, being convenient and easy to apply to a large area, being easy to terminate the medication, and avoiding gastrointestinal irritations. All these can increase patient compliance. However, there are several disadvantages to this system – causing skin irritations and symptoms like rashes and itchiness may occur. Also, only small particles can pass through the skin, which limits the choice of drugs. Since skin is the main medium of the topical drug delivery system, its conditions determine the rate of skin penetration leading to affecting the pharmacokinetics of the drug. The temperature, pH value, and dryness of the skin need to be considered. There are some novel topical drugs in the market which can utilise the system as much as possible. This localized system provides topical therapeutic effects via skin, eyes, nose, and vagina to treat diseases. The most common usage is for local skin infections.
=== Relationship Testing === BRT's Relationship Testing division offers services in Paternity Testing and Family reunification Immigration Testing. DNA testing can identify relationships between parent and child, full or half siblings, grandparent and grandchild, uncles or aunts and nieces or nephews, as well as identical and non-identical twins. The Laboratory is accredited by the AABB (formerly, American Association of Blood Banks). Testing can be performed for submission in legal proceedings (court admissible) or for personal knowledge. Application for immigration to the United States and Canada often requires documentation of biological relationship between a petitioner and his or her beneficiary. DNA testing can be used to prove a relationship if documents are absent or challenged. The US Immigration and Naturalization Service (INS) and United States Citizenship and Immigration Services (USCIS) offices accept DNA testing results from AABB accredited laboratories only.
== Research contributions == Balalaie's research focuses on several areas of organic chemistry, including environmentally friendly synthetic methods and pharmaceutical applications. His research group has worked on the development of multicomponent reactions (MCRs), particularly for the synthesis of heterocyclic compounds. His work in this area has included the use of zeolite catalysts for the preparation of tetrasubstituted imidazoles and other heterocycles. His research has also involved developing synthetic routes for several active pharmaceutical ingredients (APIs). Compounds published by his group include: Zoledronic acid, Gabapentin, Deferasirox and Pantoprazole. In peptide synthesis, Balalaie's work has included the synthesis of therapeutic peptides such as triptorelin, leuprolide, octreotide, and oxytocin. His group has also designed cyclopeptides containing heterocyclic structures (imidazole, thiazole, oxazole) intended to serve as potential anticancer agents. His book "Peptide Chemistry in Persian" was recognized as a winner of the Iran Book of the Year Award in 1399 (2020).
Sources: en.wikipedia.org
ATP + H2O + oligopeptide [oligopeptide - binding protein][side 1] = ADP + phosphate + oligopeptide [side 2] + [oligopeptide - binding protein][side 1] 7.4.2.7 ABC-type alpha-factor-pheromone transporter The enzyme appears in viruses and cellular organisms characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. Does not undergo phosphorylation during the transport process. A yeast enzyme that exports the α-factor sex pheromone. ATP + H2O + alpha factor [side 1] = ADP + phosphate + alpha factor [side 2] 7.4.2.8 ABC-type protein-secreting ATPase The expected taxonomic range for this enzyme is: Archaea, Bacteria. A non-phosphorylated, non-ABC (ATP-binding cassette) ATPase that is involved in protein transport. ATP + H2O + cellular protein [side 1] = ADP + phosphate + cellular protein [side 2] 7.4.2.9 ABC-type dipeptide transporter The enzyme appears in viruses and cellular organisms. ATP-binding cassette (ABC) type transporter, characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. A bacterial enzyme that interacts with an extracytoplasmic substrate binding protein and mediates the uptake of dipeptides and tripeptides.
On 2 September 1919, the Francesco Saverio Nitti government issued the Visocchi Decree (named after the Minister of Agriculture, Achille Visocchi), which gave prefects the power to temporarily assign uncultivated land for four years to peasants formed in legally constituted leagues or agrarian bodies. A permit issued by a committee composed equally of peasant and landowner representatives, under prefectorial control, was required to obtain the assignment, which specified the duration of occupation and the rental price (paid by the peasants). However, seven months later, the redistribution had limited effects: only an estimated 27,000 hectares were allocated. The decree was criticized by both conservatives and socialists: Arrigo Serpieri, later minister of agriculture in the Fascist period, judged the measure “one of the most infamous of the postwar period”, while socialist Filippo Turati deemed it too “timid”.
=== Legal status === In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ablymico, indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity. The applicant for this medicinal product is STADA Arzneimittel AG. Ablymico is a hybrid medicine of liraglutide (Saxenda), which has been authorized in the European Union since March 2015. Ablymico contains the same active substance as Saxenda, but it is chemically synthesized, whereas the active substance in the reference products is of biological origin. Ablymico was authorized for medical use in the European Union in July 2026. In May 2026, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Liraglutide Stada, intended for the treatment of insufficiently controlled type 2 diabetes. The applicant for this medicinal product is STADA Arzneimittel AG. Liraglutide Stada is a hybrid medicine of liraglutide (Victoza), which has been authorized in the European Union since June 2009. Liraglutide Stada contains the same active substance as Victoza, but it is chemically synthesized, whereas the active substance in the reference products is of biological origin.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.